In this episode, Martin discusses developments around a potential oral PGL-1 breakthrough and what it could mean for the broader biotech landscape. He also walks through an advanced transcript on Godel, explaining how he uses it to analyze complex scientific and market information.
In this episode, Martin discusses why he believes private equity has already positioned itself in what could become the next Nvidia. He examines what this early institutional interest may signal for the future of AI stocks and outlines how he’s thinking about the next phase of the sector’s growth.
Panel: Martin Shkreli, Adrian Dittmann, Outa.
Recorded on 12/23/2025.
In this episode, Martin recounts his claim that the SEC restricted his trading account and discusses how this affects his ability to manage positions moving forward. He explains why he still isn’t finished with his CAPR thesis, then shifts to broader market topics, including his outlook on Intel and emerging developments in photonic computing.
In this episode, Martin describes how a major trading setback forced him to rethink his approach and pivot professionally. He walks through what happened during the CAPR short squeeze, the market dynamics that drove it, and the lessons he drew from managing the aftermath of the trade.
In this episode, Martin compares the stability of AAA bonds with the current state of the broader market, explaining how risk-adjusted returns stack up between the two. He also walks through his approach to valuing AstraZeneca’s drug pipeline, examining key assets, projected timelines, and the factors that shape his long-term outlook on the company.
In this episode, Martin takes a deep look at AstraZeneca, highlighting two major areas of potential he sees within the company’s long-term strategy. He breaks down AZN’s drug portfolio, reviews its key clinical programs, and explains how these components shape his perspective on the stock’s future performance.
In this episode, Martin examines Google’s continued momentum, focusing on how its TPU strategy is driving renewed market optimism. He also reviews a weakening forecast for Novo Nordisk, breaking down the factors behind the shift and what it could mean for the company’s long-term outlook. The episode closes with his broader analysis of how these developments fit into current market trends.
In this episode, Martin explains why he thinks the market may be setting up for another rally and identifies what he considers his safest long position in the current environment. He also discusses why he believes CAPR could face a sharp decline, and shares updated views on Nvidia and IonQ as shifting market conditions continue to shape his strategy.
In this episode, Martin weighs in on whether a Santa Claus rally is possible amid growing signs of market strain. He discusses consumer overspending, the latest developments surrounding OpenAI, and the broader signs he believes point to a bubble nearing its breaking point.
In this episode, Martin outlines five guiding rules he uses to anticipate major market turns, applying them specifically to Nvidia’s current position in the semiconductor cycle. He discusses whether the industry may be approaching a peak and shares his broader market forecast based on these indicators.
In this episode, Martin explains why he believes a true bear market has arrived and breaks down Nvidia’s latest earnings to assess how the company may perform in a shifting environment. He also considers whether Agios could be a worthwhile long position, reviewing the fundamentals and potential catalysts shaping its outlook.
In this episode, Martin revisits the bearish case against Nvidia and explains why some of the skepticism may be more reasonable than it first appeared. He also reviews developments at United Therapeutics and takes a closer look at Encoded Therapeutics, outlining how each fits into his current market outlook.
In this episode, Martin argues that even strong Nvidia earnings won’t be enough to stabilize a market he believes is heading for a deeper decline. He also delivers an in-depth analysis of CoreWeave (CRWV), examining its business model, financial structure, and how current industry pressures may impact the stock.
In this episode, Martin discusses what he views as a major emerging threat for biotech investors and how it could reshape the pharmaceutical landscape. He also reviews recent discussions and market reactions surrounding AVXL, focusing on concerns that have been raised about its data and how he interprets these issues as a trader.
In this compilation episode, Martin shares some of his most valuable investing lessons and insights—concepts that he says many people pay large sums to learn. The episode brings together highlights from past discussions on valuation, risk management, and strategy, offering a concise masterclass in practical investing.
In this episode, Martin reacts to the latest news surrounding Anavex (AVXL) and explains why he believes the short trade may still have room to run. He breaks down recent market reactions, reviews his trading thesis, and discusses how new information could influence the stock’s next moves.
In this episode, Martin discusses how executive compensation structures can inform short sellers about a company’s priorities and potential red flags. He also examines Anavex’s stock and reviews concerns that have been raised about its clinical trial data, explaining how he interprets the available information from an investor’s perspective.
In this episode, Martin sets his sights on achieving 1000% year-to-date gains and outlines the high-risk trades he’s taking to reach that goal. He discusses his short position in Anavex ($AVXL), explaining his reasoning and evidence behind calling out what he views as a “scam trial,” and shares broader thoughts on risk-taking and conviction in biotech trading.
In this episode, Martin explains his strategy for selling CAPR and managing his ongoing Sarepta recovery trade. He also discusses recent developments involving Sam Altman and shares his thoughts on the “Burning Apes” phenomenon, connecting each topic to broader market behavior and investor sentiment.